Literature DB >> 9426411

Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients.

G Q Phan1, C J Yeo, J L Cameron, M M Maher, R H Hruban, R Udelsman.   

Abstract

BACKGROUND: Most resectable pancreatic or peripancreatic neuroendocrine tumors are treated by enucleation or distal pancreatectomy. A minority of tumors may require pancreaticoduodenectomy for complete tumor excision because of their large size, location, or lymph node involvement.
METHODS: This study reviews the management of 50 patients treated by pancreaticoduodenectomy for periampullary neuroendocrine tumors between 1962 and 1996 at a single institution.
RESULTS: There were 30 men and 20 women with a mean age of 52 +/- 2 years. Functional tumors were resected in 17 patients: insulinoma, seven tumors; gastrinoma, eight tumors; vipoma, one tumor; and glucagonoma, one tumor. Tumors were classified as malignant in 29 patients and benign in 21. The median intraoperative blood loss was 800 ml, and the median number of units of blood transfused was zero. The postoperative length of stay was 20 +/- 2 days. Postoperative morbidity included 11 patients (24%) with a pancreatic fistula and four patients (8%) with a biliary fistula. There was one in-hospital death (2%), in 1967. The actuarial survival rates at 2, 5, and 7 years are 81%, 73%, and 65%, respectively. Patients with benign tumors had a significantly improved 5-year survival rate (94%) compared with those with malignant tumors (61%; p = 0.03).
CONCLUSIONS: Selected patients with periampullary neuroendocrine tumors can be managed successfully by pancreaticoduodenectomy, with low mortality and acceptable morbidity rates.

Entities:  

Mesh:

Year:  1997        PMID: 9426411     DOI: 10.1016/s0039-6060(97)90200-2

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.

Authors:  Detlef K Bartsch; Volker Fendrich; Peter Langer; Ilhan Celik; Peter H Kann; Matthias Rothmund
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis.

Authors:  Zina Meriden; Chanjuan Shi; Barish H Edil; Trevor Ellison; Christopher L Wolfgang; Toby C Cornish; Richard D Schulick; Ralph H Hruban
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

4.  Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Authors:  Hiromichi Ito; Michael Abramson; Kaori Ito; Edward Swanson; Nancy Cho; Daniel T Ruan; Richard S Swanson; Edward E Whang
Journal:  J Gastrointest Surg       Date:  2010-03-12       Impact factor: 3.452

5.  Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.

Authors:  T C Lairmore; V Y Chen; M K DeBenedetti; W E Gillanders; J A Norton; G M Doherty
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

6.  Quality of life and outcomes after pancreaticoduodenectomy.

Authors:  J J Huang; C J Yeo; T A Sohn; K D Lillemoe; P K Sauter; J Coleman; R H Hruban; J L Cameron
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

Review 7.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

Review 8.  Ampullary carcinoid tumors: rationale for an aggressive surgical approach.

Authors:  Wilson M Clements; Stephen P Martin; Grant Stemmerman; Andrew M Lowy
Journal:  J Gastrointest Surg       Date:  2003 Sep-Oct       Impact factor: 3.452

9.  Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients.

Authors:  G Q Phan; C J Yeo; R H Hruban; K D Littemoe; H A Pitt; J L Cameron
Journal:  J Gastrointest Surg       Date:  1998 Sep-Oct       Impact factor: 3.452

Review 10.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.